Youcare Pharmaceutical (SH:688658) Mei Ri Jing Ji Xin Wen·2026-01-30 08:26Core Viewpoint - Yuyuan Pharmaceutical Group Co., Ltd. expects a net profit attributable to shareholders of the parent company to be between -280 million to -235 million yuan for the year 2025, indicating a loss compared to the same period last year [1] Financial Performance - The company anticipates a significant decline in revenue and profit due to adjustments in pricing and sales strategy for its product "Ginkgo Biloba Extract Injection" at the end of 2024 [1] - The high proportion of R&D investment has impacted the company's net profit, with R&D expenses increasing year-on-year [1] Strategic Initiatives - The company remains committed to its long-term development strategy, continuously adjusting and improving its operational strategies to enhance efficiency [1] - Yuyuan Pharmaceutical is focused on maintaining the stability of its core sales channels and strengthening its core competitiveness and investment value [1] - The company places a strong emphasis on R&D innovation as a strategic priority and is actively promoting new drug development projects [1]